Medical

According to Chiesi Group, a Phase 1 trial of its inhaled phosphodiesterase 4 (PDE4) inhibitor for the treatment of lung diseases such as COPD and asthma demonstrated that the drug, known as CHF 6001, was well tolerated in healthy volunteers at doses of up to 2000 µg for up to 7 days. In vitro and animal studies have shown that CHF 6001 is more potent than … [Read more...] about Chiesi announces positive Phase 1 results for its inhaled PDE4 inhibitor

An article posted on October 4, 2012 on the BMJ publication Drug and Therapeutics Bulletin article asks, "who needs teaching?" when it comes to inhaler technique. The article points out that an overwhelming number of health professionals have a poor understanding of how to use inhalers and are therefore in no position to teach patients how to use the devices. The … [Read more...] about Drug and Therapeutics Bulletin article warns that health professionals do not understand how to use inhalers properly

MannKind Corporation says that it has completed recruitment of patients for two Phase 3 studies of Afrezza inhaled insulin. One of the studies will assess HbA1c levels in Type 1 diabetes patients using either injected rapid-acting insulin, Afrezza delivered with the MedTone inhaler, or Afrezza delivered by MannKind's next generation inhaler. The second study involves … [Read more...] about MannKind completes patient recruitment for two Afrezza studies

OptiNose has announced results of a randomized, single-dose, four-way cross-over PK study demonstrating that 20% less of its intranasal dry powder sumatriptan product delivered into the nose than Imitrex nasal spray resulted in over 60% more sumatriptan in the blood in the first 15 minutes. The 16 mg dose of the Optinose product also resulted in over 30% more in … [Read more...] about Study shows better absorption for dry powder intranasal sumatriptan than nasal or oral Imitrex

MicroDose Therapeutx has completed the Phase 1 clinical program for its inhaled antiviral fusion inhibitor MDT-637 for the treatment of respiratory syncytial virus infection and plans to present data from the three studies at the upcoming International Respiratory Syncytial Virus Symposium. The company announced completion of the first two studies in April 2012. … [Read more...] about Microdose announces completion of Phase 1 studies for inhaled RSV treatment

Belgian biopharmaceutical company Ablynx has announced positive results from a Phase 1 of its ALX-0171 inhaled Nanobody for the treatment of respiratory syncytial virus (RSV) infections. According to the company, the study demonstrated the safety and tolerability of ALX-0171 delivered by nebulizer. The double-blind, randomized trial tested six dose levels ranging … [Read more...] about Ablynx completes Phase 1 study of inhaled nanobody for RSV

Pearl Therapeutics says that it has completed a Phase 2b dose-ranging study of its PT001 glycopyrrolate (GP) metered dose inhaler in patients with moderate-to-severe COPD. The randomized, double-blind study included 6 doses from 18 µg to 600 ng twice daily. According to Pearl, it will present data from its dose-ranging studies of PT001 at "appropriate medical … [Read more...] about Pearl Therapeutics completes Phase 2b study of glycopyrrolate MDI

According to Boehringer Ingelheim, a combination of tiotropium and olodaterol delivered using the Respimat soft mist inhaler significantly improved 24-hour FEV1 in COPD patients compared to olodaterol monotherapy at all doses tested. The 4-week double-blind study with 232 COPD patients testing doses of tiotropium of 1.25, 2.5, and 5 μg with either 5 μg or 10 μg of … [Read more...] about Tiotropium plus olodaterol improve lung function in Phase 2 study

Rigel Pharmaceuticals says that it has begun a Phase 2 clinical study of its R343 nhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. The 8-week study, called SITAR (SYK Inhibition for Treatment of Asthma with R343), will compare two doses R343 and placebo in approximately 270 adult asthma patients and is expected to be completed … [Read more...] about Rigel initiates Phase 2 study of inhaled SYK inhibitor for asthma